Referenzen und Quellen
Vita 34 steht für Transparenz: Für unseren Beiträge in Fachmagazinen führen wir deswegen hier alle Quellen und Referenzen auf.
Beiträge Basiswissen:
Stammzellen aus der Nabelschnur – Basiswissen und Stand der Wissenschaft
1. Begemann H. Das Blut als Organ. In: Begemann H, Bolck F, Lang FJ, et al., eds. Die Organe: Die Organstruktur als Grundlage der Organleistung und Organerkrankung I. Berlin, Heidelberg: Springer Berlin Heidelberg; 1960:1-43.
2. Bundesärztekammer. Richtlinie zur Herstellung und Anwendung von hämatopoetischen Stammzellzubereitungen. Deutsches Ärzteblatt. 2014.
3. Wang Y, Zhao S. Placental Blood Circulation. https://www.ncbi.nlm.nih.gov/books/NBK53254/. Updated January 1, 2010. Accessed April 30, 2019.
4. Christou I, Mallis P, Michalopoulos E, et al. Evaluation of Peripheral Blood and Cord Blood Platelet Lysates in Isolation and Expansion of Multipotent Mesenchymal Stromal Cells. Bioengineering (Basel). 2018;5(1). doi:10.3390/bioengineering5010019.
5. Bundesamt für Justiz. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz – AMG) § 13 Herstellungserlaubnis. https://www.gesetze-im-internet.de/amg_1976/__13.html. Updated July 22, 2019. Accessed July 22, 2019.
6. Bundesamt für Justiz. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz – AMG) § 21 Zulassungspflicht. https://www.gesetze-im-internet.de/amg_1976/__21.html. Updated July 22, 2019. Accessed July 22, 2019.
7. Bundesamt für Justiz. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz – AMG) § 21a Genehmigung von Gewebezubereitungen. https://www.gesetze-im-internet.de/amg_1976/__21a.html. Updated July 22, 2019. Accessed July 22, 2019.
8. Bundesamt für Justiz. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz – AMG) § 22 Zulassungsunterlagen. https://www.gesetze-im-internet.de/amg_1976/__22.html. Updated July 22, 2019. Accessed July 22, 2019.
9. Bundesamt für Justiz. Verordnung über die Anwendung der Guten Herstellungspraxis bei der Herstellung von Arzneimitteln und Wirkstoffen und über die Anwendung der Guten fachlichen Praxis bei der Herstellung von Produkten menschlicher Herkunft (Arzneimittel- und Wirkstoffherstellungsverordnung – AMWHV) § 4 Personal. https://www.gesetze-im-internet.de/amwhv/__4.html. Updated July 22, 2019. Accessed July 22, 2019.
10. Galieva LR, Mukhamedshina YO, Arkhipova SS, Rizvanov AA. Human Umbilical Cord Blood Cell Transplantation in Neuroregenerative Strategies. Front Pharmacol. 2017;8:628. doi:10.3389/fphar.2017.00628.
11. Sieburg HB, Cattarossi G, Muller-Sieburg CE. Lifespan differences in hematopoietic stem cells are due to imperfect repair and unstable mean-reversion. PLoS Comput Biol. 2013;9(4):e1003006. doi:10.1371/journal.pcbi.1003006.
12. Pillay J, den Braber I, Vrisekoop N, et al. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood. 2010;116(4):625-627. doi:10.1182/blood-2010-01-259028.
13. Park YM, Bochner BS. Eosinophil survival and apoptosis in health and disease. Allergy Asthma Immunol Res. 2010;2(2):87-101. doi:10.4168/aair.2010.2.2.87.
14. Siracusa MC, Comeau MR, Artis D. New insights into basophil biology: initiators, regulators, and effectors of type 2 inflammation. Ann N Y Acad Sci. 2011;1217:166-177. doi:10.1111/j.1749-6632.2010.05918.x.
15. Patel AA, Zhang Y, Fullerton JN, et al. The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. J Exp Med. 2017;214(7):1913-1923. doi:10.1084/jem.20170355.
16. Kaestner L, Bogdanova A. Regulation of red cell life-span, erythropoiesis, senescence, and clearance. Front Physiol. 2014;5:269. doi:10.3389/fphys.2014.00269.
17. Franco RS. Measurement of red cell lifespan and aging. Transfus Med Hemother. 2012;39(5):302-307. doi:10.1159/000342232.
18. Seifert M, Küppers R. Human memory B cells. Leukemia. 2016;30(12):2283-2292. doi:10.1038/leu.2016.226.
19. Broxmeyer HE. StemBook: Cord blood hematopoietic stem cell transplantation∗. Cambridge (MA); 2008. https://www.ncbi.nlm.nih.gov/books/NBK44751/. Accessed April 29, 2019.
20. Jin HJ, Bae YK, Kim M, et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci. 2013;14(9):17986-18001. doi:10.3390/ijms140917986.
21. Davies JE, Walker JT, Keating A. Concise Review: Wharton’s Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells. Stem Cells Transl Med. 2017;6(7):1620-1630. doi:10.1002/sctm.16-0492.
22. Marino L, Castaldi MA, Rosamilio R, et al. Mesenchymal Stem Cells from the Wharton’s Jelly of the Human Umbilical Cord: Biological Properties and Therapeutic Potential. Int J Stem Cells. 2019. doi:10.15283/ijsc18034.
23. Dalous J, Larghero J, Baud O. Transplantation of umbilical cord-derived mesenchymal stem cells as a novel strategy to protect the central nervous system: technical aspects, preclinical studies, and clinical perspectives. Pediatr Res. 2012;71(4 Pt 2):482-490. doi:10.1038/pr.2011.67.
24. Willing AE, Eve DJ, Sanberg PR. Umbilical cord blood transfusions for prevention of progressive brain injury and induction of neural recovery: an immunological perspective. Regen Med. 2007;2(4):457-464. doi:10.2217/17460751.2.4.457.
25. Balassa K, Rocha V. Anticancer cellular immunotherapies derived from umbilical cord blood. Expert Opin Biol Ther. 2018;18(2):121-134. doi:10.1080/14712598.2018.1402002.
26. Bönig H, Heiden M, Schüttrumpf J, Müller MM, Seifried E. Potenzial hämatopoetischer Stammzellen als Ausgangsmaterial für Arzneimittel für neuartige Therapien. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2011;54(7):791-796. doi:10.1007/s00103-011-1305-2.
27. Mayani H, Wagner JE, Broxmeyer HE. Cord blood research, banking, and transplantation: achievements, challenges, and perspectives. Bone Marrow Transplant. 2019. doi:10.1038/s41409-019-0546-9.
28. Gluckman Eliane, Broxmeyer Hal E., Auerbach Arleen D., et al. Hematopoietic Reconstitution in a Patient with Fanconi’s Anemia by Means of Umbilical-Cord Blood from an HLA-Identical Sibling // Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321(17):1174-1178. doi:10.1056/NEJM198910263211707.
29. Dessels C, Alessandrini M, Pepper MS. Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape. Stem Cells Transl Med. 2018;7(9):643-650. doi:10.1002/sctm.17-0244.
30. Ballen K. Update on umbilical cord blood transplantation. F1000Res. 2017;6:1556. doi:10.12688/f1000research.11952.1.
31. ClinicalTrials.gov. NCT03913312: Multicenter, One-arm, Phase II Clinical Study of Decitabine Combined With Unrelated Cord Blood Transplantation for the Treatment of Acute Myeloid Leukemia (AML) in the Elderly. https://clinicaltrials.gov/ct2/show/NCT03913312. Accessed June 20, 2019.
32. ClinicalTrials.gov. NCT03441958: A Phase I-II Open-label Study of Non-myeloablative-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With High-risk Multiple Myeloma. https://clinicaltrials.gov/ct2/show/NCT03441958. Accessed June 20, 2019.
33. ClinicalTrials.gov. NCT01451502: Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units. https://clinicaltrials.gov/ct2/show/NCT01451502. Accessed June 20, 2019.
34. ClinicalTrials.gov. NCT02745717: The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia. https://clinicaltrials.gov/ct2/show/NCT02745717. Accessed June 20, 2019.
35. ClinicalTrials.gov. NCT02838992: Multi-center Clinical Study of Immunosuppressants, Cyclophosphamide, And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia. https://clinicaltrials.gov/ct2/show/NCT02838992. Accessed June 20, 2019.
36. ClinicalTrials.gov. NCT03881774: Clinical Study of Cord Blood Derived CAR-T Cells in Patients With Refractory/Relapsed B Cell Leukemia/Lymphoma Who Are Failed for Autologous CAR-T Cells or Autologous CAR-T Can Not be Prepared. https://clinicaltrials.gov/ct2/show/NCT03881774?term=%22cord+blood%22%2C+%22CAR+T%22&rank=1. Accessed June 18, 2019.
37. ClinicalTrials.gov. NCT01861093: A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients. https://clinicaltrials.gov/ct2/show/NCT01861093. Accessed June 20, 2019.
38. ClinicalTrials.gov. NCT01768845: Unrelated Umbilical Cord Blood (UBC)Transplantation. https://clinicaltrials.gov/ct2/show/NCT01768845. Accessed June 20, 2019.
39. ClinicalTrials.gov. NCT01247701: Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies (UCAML). https://clinicaltrials.gov/ct2/show/NCT01247701. Accessed June 21, 2019.
40. ClinicalTrials.gov. NCT00739141: A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. https://clinicaltrials.gov/ct2/show/NCT00739141. Accessed June 21, 2019.
41. ClinicalTrials.gov. NCT01553461: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications. https://clinicaltrials.gov/ct2/show/NCT01553461. Accessed June 21, 2019.
42. ClinicalTrials.gov. NCT02730299: A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies. https://clinicaltrials.gov/ct2/show/NCT02730299. Accessed June 21, 2019.
43. ClinicalTrials.gov. NCT01962636: Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases. https://clinicaltrials.gov/ct2/show/NCT01962636. Accessed June 21, 2019.
44. ClinicalTrials.gov. NCT03096782: Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment. https://clinicaltrials.gov/ct2/show/NCT03096782. Accessed June 21, 2019.
45. ClinicalTrials.gov. NCT01619761: Natural Killer Cells in Allogeneic Cord Blood Transplantation. https://clinicaltrials.gov/ct2/show/NCT01619761. Accessed June 20, 2019.
46. ClinicalTrials.gov. NCT02727803: Personalized NK Cell Therapy in Cord Blood Transplantation. https://clinicaltrials.gov/ct2/show/NCT02727803. Accessed June 20, 2019.
47. ClinicalTrials.gov. NCT03579927: Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived CAR-NK Cells Combined With High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-Cell Lymphoma. https://clinicaltrials.gov/ct2/show/NCT03579927. Accessed June 20, 2019.
48. ClinicalTrials.gov. NCT01729091: Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma. https://clinicaltrials.gov/ct2/show/NCT01729091. Accessed June 20, 2019.
49. ClinicalTrials.gov. NCT02280525: A Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Lymphodepleting Chemotherapy and Lenalidomide as Immunotherapy in Patients With Hematologic Malignancies. https://clinicaltrials.gov/ct2/show/NCT02280525. Accessed June 20, 2019.
50. ClinicalTrials.gov. NCT03056339: Dose Escalation Study Phase I/II of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction With Lymphodepleting Chemotherapy in Patients With Relapsed/Refractory B-Lymphoid Malignancies. https://clinicaltrials.gov/ct2/show/NCT03056339?term=%22cord+blood%22%2C+CAR%2C+NK&rank=1. Accessed June 18, 2019.
51. ClinicalTrials.gov. NCT03420963: Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults. https://clinicaltrials.gov/ct2/show/NCT03420963. Accessed June 20, 2019.
52. ClinicalTrials.gov. NCT03735277: Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke. https://clinicaltrials.gov/ct2/show/NCT03735277. Accessed June 21, 2019.
53. ClinicalTrials.gov. NCT02433509: Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke. https://clinicaltrials.gov/ct2/show/NCT02433509. Accessed June 21, 2019.
54. ClinicalTrials.gov. NCT01673932: Phase 1 Clinical Trial to Establish the Safety and Feasibility of Transplants of Umbilical Cord Blood Mononuclear Cells in Chronic Ischemic Stroke. https://clinicaltrials.gov/ct2/show/NCT01673932. Accessed June 21, 2019.
55. ClinicalTrials.gov. NCT03791372: Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy. https://clinicaltrials.gov/ct2/show/NCT03791372. Accessed June 21, 2019.
56. ClinicalTrials.gov. NCT02551003: A Multi-Centre Safety and Efficacy Study of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonates Encephalopathy in China. https://clinicaltrials.gov/ct2/show/NCT02551003. Accessed June 21, 2019.
57. ClinicalTrials.gov. NCT02612155: A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy. https://clinicaltrials.gov/ct2/show/NCT02612155. Accessed May 29, 2019.
58. ClinicalTrials.gov. NCT03696745: The Treatment of Premature Infants With Brain Injury by Autologous Umbilical Cord Blood Stem Cells. https://clinicaltrials.gov/ct2/show/NCT03696745. Accessed June 21, 2019.
59. ClinicalTrials.gov. NCT02952716: Treatment of Human Cord Blood Mononuclear Cell for Delayed Encephalopathy After Carbon Monoxide Poisoning. https://clinicaltrials.gov/ct2/show/NCT02952716. Accessed June 21, 2019.
60. ClinicalTrials.gov. NCT03352310: Umbilical Cord Blood Mononuclear Cell Bank in Hong Kong and Treatment of Neonatal Cerebral Ischemia and Anemia – Part IV Clinical Trial. https://clinicaltrials.gov/ct2/show/NCT03352310. Accessed June 21, 2019.
61. ClinicalTrials.gov. NCT01072370: A Placebo-Controlled, Observer-Blinded, Crossover Study to Evaluate the Safety and Effectiveness of a Single, Autologous, Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children. https://clinicaltrials.gov/ct2/show/NCT01072370. Accessed June 21, 2019.
62. ClinicalTrials.gov. NCT03473301: A Phase I/II Study of Allogeneic Umbilical Cord Blood and Umbilical Cord Tissue-Derived Mesenchymal Stromal Cell Infusions in Children With Cerebral Palsy. https://clinicaltrials.gov/ct2/show/NCT03473301?term=kurtzberg&rank=3. Accessed June 13, 2019.
63. ClinicalTrials.gov. NCT02881970: Neonatal Hypoxic Ischemic Encephalopathy : Safety and Feasibility Study of a Curative Treatment With Autologous Cord Blood Stem Cells (NEOSTEM). https://clinicaltrials.gov/ct2/show/NCT02881970. Accessed June 21, 2019.
64. ClinicalTrials.gov. NCT03826498: Allogenic Cord Blood Transfusion in Patients With Cerebral Palsy. https://clinicaltrials.gov/ct2/show/NCT03826498. Accessed June 21, 2019.
65. ClinicalTrials.gov. NCT03558269: Pilot Study to Assess the Efficacy of Autologous Umbilical Cord Blood Treatment of Brain and Heart Injury in Neonates With Congenital Heart Defect. https://clinicaltrials.gov/ct2/show/NCT03558269. Accessed June 21, 2019.
66. ClinicalTrials.gov. NCT03431480: Safety Study of Autologous Cord Blood Stem Cell Treatment in Hypoplastic Left Heart Syndrome Patients Undergoing the Norwood Heart Operation. https://clinicaltrials.gov/ct2/show/NCT03431480. Accessed June 21, 2019.
67. ClinicalTrials.gov. NCT01883076: Phase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart Syndrome. https://clinicaltrials.gov/ct2/show/NCT01883076. Accessed June 21, 2019.
68. ClinicalTrials.gov. NCT03779711: Phase IIb Study of Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Stage II Surgical Repair of Right Ventricular Dependent Variants of Hypoplastic Left Heart Syndrome (AutoCell-S2). https://clinicaltrials.gov/ct2/show/NCT03779711. Accessed June 21, 2019.
69. ClinicalTrials.gov. NCT03855202: The Treatment of Bronchopulmonary Dysplasia by Instillation PS and Mononuclaer Cells in Preterms. https://clinicaltrials.gov/ct2/show/NCT03855202. Accessed June 21, 2019.
70. ClinicalTrials.gov. NCT01897987: Follow-up Safety and Efficacy Evaluation on Subjects Who Completed the Initial Stage of PNEUMOSTEM® Phase-II Clinical Trial. https://clinicaltrials.gov/ct2/show/NCT01897987. Accessed June 21, 2019.
71. ClinicalTrials.gov. NCT01632475: Long Term Follow-Up Study of the Safety and Exploratory Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia. https://clinicaltrials.gov/ct2/show/NCT01632475. Accessed June 21, 2019.
72. ClinicalTrials.gov. NCT03378063: Stem Cells for Bronchopulmonary Dysplasia: a Cohort Study. https://clinicaltrials.gov/ct2/show/NCT03378063?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=124. Accessed June 21, 2019.
73. ClinicalTrials.gov. NCT02932826: Phase 1/ Phase 2 Study of the Therapeutic Effect of Ex-vivo Expanded Umbilical Cord Blood Regulatory T Cells on Autoimmune Diabetes. https://clinicaltrials.gov/ct2/show/NCT02932826. Accessed June 21, 2019.
74. ClinicalTrials.gov. NCT03835312: Sequential Transplantation of Umbilical Cord Blood Stem Cells and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency Type 1 Diabetes Mellitus. https://clinicaltrials.gov/ct2/show/NCT03835312. Accessed June 21, 2019.
75. ClinicalTrials.gov. NCT03011021: Phase 1/ Phase 2 Study of the Therapeutic Effect of Ex-vivo Expanded Umbilical Cord Blood Regulatory T Cells With Liraglutide on Autoimmune Diabetes. https://clinicaltrials.gov/ct2/show/NCT03011021. Accessed June 21, 2019.
76. ClinicalTrials.gov. NCT03016806: Umbilical Cord Blood Transplantation From Unrelated Donors. https://clinicaltrials.gov/ct2/show/NCT03016806. Accessed June 21, 2019.
77. ClinicalTrials.gov. NCT03269773: A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis. https://clinicaltrials.gov/ct2/show/NCT03269773?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=141. Accessed June 21, 2019.
78. ClinicalTrials.gov. NCT02926300: Extension Study, An Open-labelled, Multi Center, Comparative Phase I/IIa Clinical Trials to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn’s Disease. https://clinicaltrials.gov/ct2/show/NCT02926300?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=142. Accessed June 21, 2019.
79. ClinicalTrials.gov. NCT02918123: Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis. https://clinicaltrials.gov/ct2/show/NCT02918123?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=143. Accessed June 21, 2019.
80. ClinicalTrials.gov. NCT03618784: A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase I/2a Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. for Moderate to Severe Rheumatoid Arthritis. https://clinicaltrials.gov/ct2/show/NCT03618784?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=131. Accessed June 21, 2019.
81. ClinicalTrials.gov. NCT02254863: Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells. https://clinicaltrials.gov/ct2/show/NCT02254863. Accessed June 21, 2019.
82. ClinicalTrials.gov. NCT03084861: A Multicenter, Randomized, Open-label, Two-arms Phase I/II Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy. https://clinicaltrials.gov/ct2/show/NCT03084861. Accessed June 21, 2019.
83. ClinicalTrials.gov. NCT03676400: Clinical Study for the Assessment of the Hair Growth Efficacy and Safety of a Cosmetic Investigational Product, After Repeated Applications for 24 Weeks, Under Normal Conditions of Use, in the Asian Adult Subjects With Androgenic Alopecia. https://clinicaltrials.gov/ct2/show/NCT03676400. Accessed June 21, 2019.
84. ClinicalTrials.gov. NCT02434965: Autologous Cord Blood and Human Placental Derived Stem Cells in Neonates With Severe Hypoxic-Ischemic Encephalopathy. https://clinicaltrials.gov/ct2/show/NCT02434965?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&rank=11. Accessed August 9, 2019.
85. Weyand M, Kececioglu D, Schulze-Everding A, et al. Die chirurgischen Behandlungsmöglichkeiten des Hypoplastischen Linksherzsyndroms. Dtsch Arztebl International. 1998;95(37):A-2256. https://www.aerzteblatt.de/int/article.asp?id=13039.
86. ClinicalTrials.gov. NCT03779711: Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome (AutoCell-S2). https://clinicaltrials.gov/ct2/show/NCT03779711?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&rank=37. Accessed May 29, 2019.
87. ClinicalTrials.gov. NCT02054208: Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer’s Disease. https://clinicaltrials.gov/ct2/show/NCT02054208?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&rank=78. Accessed May 29, 2019.
88. Hansen M, Zatula N, Riammer S, Lehmann M. Safe enzymatic isolation and expansion of mesenchymal stromal cells from cryopreserved umbilical cord tissue. JCB. 2019;4(1-2):51-56. doi:10.3233/JCB-180011.
89. Beeravolu N, McKee C, Alamri A, et al. Isolation and Characterization of Mesenchymal Stromal Cells from Human Umbilical Cord and Fetal Placenta. J Vis Exp. 2017;(122). doi:10.3791/55224.
90. Arutyunyan I, Elchaninov A, Makarov A, Fatkhudinov T. Umbilical Cord as Prospective Source for Mesenchymal Stem Cell-Based Therapy. Stem Cells Int. 2016;2016:6901286. doi:10.1155/2016/6901286.
91. Park YB, Ha CW, Kim JA, et al. Single-stage cell-based cartilage repair in a rabbit model: cell tracking and in vivo chondrogenesis of human umbilical cord blood-derived mesenchymal stem cells and hyaluronic acid hydrogel composite. Osteoarthr Cartil. 2017;25(4):570-580. doi:10.1016/j.joca.2016.10.012.
92. Kargozar S, Mozafari M, Hashemian SJ, et al. Osteogenic potential of stem cells-seeded bioactive nanocomposite scaffolds: A comparative study between human mesenchymal stem cells derived from bone, umbilical cord Wharton’s jelly, and adipose tissue. J Biomed Mater Res Part B Appl Biomater. 2018;106(1):61-72. doi:10.1002/jbm.b.33814.
93. Yang C, Wang G, Ma F, et al. Repeated injections of human umbilical cord blood-derived mesenchymal stem cells significantly promotes functional recovery in rabbits with spinal cord injury of two noncontinuous segments. Stem Cell Res Ther. 2018;9(1):136. doi:10.1186/s13287-018-0879-0.
94. Ertl J, Pichlsberger M, Tuca A-C, et al. Comparative study of regenerative effects of mesenchymal stem cells derived from placental amnion, chorion and umbilical cord on dermal wounds. Placenta. 2018;65:37-46. doi:10.1016/j.placenta.2018.04.004.
95. Moroncini G, Paolini C, Orlando F, et al. Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice. PLoS ONE. 2018;13(6):e0196048. doi:10.1371/journal.pone.0196048.
96. ClinicalTrials.gov. Search Results 06/14/2019: Keywords: „umbilical cord“ AND „mesenchymal stem cells“; Filters: Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies. 2019. https://clinicaltrials.gov/ct2/results?term=%22umbilical+cord%22%2C+%22mesenchymal+stem+cells%22&flds=abdefgikpy&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=&Search=Apply. Accessed June 14, 2019.
97. ClinicalTrials.gov. Search Results 06/14/2019: Keywords: „umbilical cord“ AND „mesenchymal stem cells“; Filters: Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies; Phase 2. 2019. https://clinicaltrials.gov/ct2/results?term=%22umbilical+cord%22%2C+%22mesenchymal+stem+cells%22&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=&phase=1&Search=Apply. Accessed June 14, 2019.
98. ClinicalTrials.gov. NCT03521323: The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Early Stage of Chronic Spinal Cord Injury：A Multicenter, Randomized, Controlled Trial. https://clinicaltrials.gov/ct2/show/NCT03521323. Accessed July 29, 2019.
99. ClinicalTrials.gov. NCT03505034: The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Late Stage of Chronic Spinal Cord Injury：A Multicenter, Prospective, Cohort Study. https://clinicaltrials.gov/ct2/show/NCT03505034. Accessed July 29, 2019.
100. ClinicalTrials.gov. NCT03521336: The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Sub-Acute Spinal Cord Injury：A Multicenter, Randomized, Controlled Trial. https://clinicaltrials.gov/ct2/show/NCT03521336. Accessed July 29, 2019.
101. ClinicalTrials.gov. NCT03795974: Evaluation of the Efficacy of Allogeneic Umbilical Cord Derived Hematopoietic Stem Cells and Mesenchymal Stromal Cells in Patients With Spastic Cerebral Palsy on Developmental Function , A Clinical Trial phase2. https://clinicaltrials.gov/ct2/show/NCT03795974. Accessed July 29, 2019.
102. ClinicalTrials.gov. NCT03414697: Transplantation of Umbilical Cord-derived Mesenchymal Stem Cells Via Different Routes for the Treatment of Cerebral Palsy in Children. https://clinicaltrials.gov/ct2/show/NCT03414697. Accessed July 29, 2019.
103. ClinicalTrials.gov. NCT03383081: A Clinical Research on the Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis. https://clinicaltrials.gov/ct2/show/NCT03383081. Accessed July 29, 2019.
104. ClinicalTrials.gov. NCT03166865: Clinical Study of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for Treatment of Knee Osteoarthritis. https://clinicaltrials.gov/ct2/show/NCT03166865. Accessed July 29, 2019.
105. ClinicalTrials.gov. NCT03818737: Randomized Multicenter Phase 3 Single-blind Trial Comparing the Efficacy of Corticosteroid Control to Mesenchymal Stem Cell Preparations From Autologous Bone Marrow Concentrate (BMAC), Adipose-derived Stem Cells in the Form of Stromal Vascular Fraction (SVF), and Third-party Human Mesenchymal Stem Cells Manufactured From Umbilical Cord Tissue for the Treatment of Unilateral Knee Osteoarthritis (OA). https://clinicaltrials.gov/ct2/show/NCT03818737. Accessed July 29, 2019.
106. ClinicalTrials.gov. NCT02968459: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars. https://clinicaltrials.gov/ct2/show/NCT02968459. Accessed July 29, 2019.
107. ClinicalTrials.gov. NCT03386708: A Clinical Research on the Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cell (19#iSCLife®-CSD) Therapy for Patients With Healing Poor After Uterus Injury. https://clinicaltrials.gov/ct2/show/NCT03386708. Accessed July 29, 2019.
108. ClinicalTrials.gov. NCT03592849: The Efficacy and Safety of Collagen Scaffold Loaded With Umbilical Cord Derived Mesenchymal Stem Cells in Infertile Women With Thin Endometrium or Endometrial Scarring. https://clinicaltrials.gov/ct2/show/NCT03592849. Accessed July 29, 2019.
109. ClinicalTrials.gov. NCT04011059: Randomized Study as Proof of Concept of Coronary Revascularization Surgery With Injection of Wharton’s Jelly-derived Mesenchymal Cells and Placement of an Epicardial Extracellular Matrix Patch Seeded With WJ-MSCs in Patients With Ischemic Cardiomyopathy. https://clinicaltrials.gov/ct2/show/NCT04011059. Accessed July 29, 2019.
110. ClinicalTrials.gov. NCT03765957: Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells. https://clinicaltrials.gov/ct2/show/NCT03765957. Accessed July 29, 2019.
111. ClinicalTrials.gov. NCT03424629: A Randomized, Positive Controlled Trial That Assess the Safety And Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cells in Moderate and Severe Plaque Psoriasis Patients. https://clinicaltrials.gov/ct2/show/NCT03424629. Accessed July 29, 2019.
112. ClinicalTrials.gov. NCT03562065: Treatment of Refractory Systemic Lupus Erythematosus by Injection of Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord. https://clinicaltrials.gov/ct2/show/NCT03562065. Accessed July 29, 2019.
113. ClinicalTrials.gov. NCT03219801: Evaluation of Safety and Efficacy in Patients With Systemic Lupus Erythematosus by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells. https://clinicaltrials.gov/ct2/show/NCT03219801. Accessed July 29, 2019.
114. ClinicalTrials.gov. NCT03580291: A Randomized, Double-Blind, Parallel-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells in Patients With Lupus Nephritis. https://clinicaltrials.gov/ct2/show/NCT03580291. Accessed July 29, 2019.
115. ClinicalTrials.gov. NCT03158896: A Phase I Study To Evaluate the Safety of Umbilical Cord – Derived, Ex-Vivo Cultured and Expanded Wharton’s Jelly Mesenchymal Stem Cells for the Treatment of De Novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease. https://clinicaltrials.gov/ct2/show/NCT03158896. Accessed June 14, 2019.
116. ClinicalTrials.gov. NCT03042143: Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST): An Open Label Dose Escalation Phase 1 Trial Followed by a Randomized, Double-blind, Placebo-controlled Phase 2 Trial. https://clinicaltrials.gov/ct2/show/NCT03042143. Accessed June 14, 2019.
117. ClinicalTrials.gov. NCT02668068: A Multicenter, Randomized, Single-blind, Parallel-group Study of Combined Large Volume WLL With Clinical Grade Umbilical Cord Mesenchymal Stem Cells(MSC) Transplantation for Treatment of Pneumoconiosis. https://clinicaltrials.gov/ct2/show/NCT02668068. Accessed June 14, 2019.
118. ClinicalTrials.gov. NCT03529136: A Prospective Multicenter Clinical Study to Evaluate The Safety and Efficiency of Human Umbilical Cord Mesenchymal Stem Cell Transfusion in Patients With Decompensated Liver Cirrhosis. https://clinicaltrials.gov/ct2/show/NCT03529136. Accessed June 14, 2019.
119. ClinicalTrials.gov. NCT03237442: Placebo-Controlled,Randomized,Double-blind Trial of Umbilical Cord Mesenchymal Stem Cells Injection for Ocular Corneal Burn. https://clinicaltrials.gov/ct2/show/NCT03237442. Accessed June 14, 2019.
120. ClinicalTrials.gov. NCT02968459: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars. https://clinicaltrials.gov/ct2/show/NCT02968459?term=%22umbilical+cord%22%2C+%22mesenchymal+stem+cells%22&recrs=abdf. Accessed June 12, 2019.
121. ClinicalTrials.gov. NCT03724617: Clinical Study of Stem Cells in the Treatment of Thin Endometrium. https://clinicaltrials.gov/ct2/show/NCT03724617. Accessed June 13, 2019.
122. ClinicalTrials.gov. NCT03818737: Randomized Multicenter Phase 3 Single-blind Trial Comparing the Efficacy of Corticosteroid Control to Mesenchymal Stem Cell Preparations From Autologous Bone Marrow Concentrate (BMAC), Adipose-derived Stem Cells in the Form of Stromal Vascular Fraction (SVF), and Third-party Human Mesenchymal Stem Cells Manufactured From Umbilical Cord Tissue for the Treatment of Unilateral Knee Osteoarthritis (OA). https://clinicaltrials.gov/ct2/show/NCT03818737. Accessed June 12, 2019.
123. Kim Y-J, Broxmeyer HE. Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance. Crit Rev Oncol Hematol. 2011;79(2):112-126. doi:10.1016/j.critrevonc.2010.07.009.
124. Sarvaria A, Basar R, Mehta RS, et al. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood. 2016;128(10):1346-1361. doi:10.1182/blood-2016-01-695122.
125. Novartis Pharma. Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) | Novartis. https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-its-car-t-cell-therapy-kymriah-tisagenlecleucel. Accessed February 28, 2019.
126. June CH, Sadelain M. Chimeric Antigen Receptor Therapy. N Engl J Med. 2018;379(1):64-73. doi:10.1056/NEJMra1706169.
127. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-448. doi:10.1056/NEJMoa1709866.
128. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531-2544. doi:10.1056/NEJMoa1707447.
129. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45-56. doi:10.1056/NEJMoa1804980.
130. ClinicalTrials.gov. NCT03579927: Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived CAR-NK Cells Combined With High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-Cell Lymphoma. https://clinicaltrials.gov/ct2/show/NCT03579927?term=%22cord+blood%22%2C+CAR%2C+NK&rank=2. Accessed June 18, 2019.
131. National Cancer Institute. CAR T Cells: Engineering Immune Cells to Treat Cancer. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells. Updated December 14, 2017. Accessed March 19, 2019.
132. Novartis Pharma. Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice | Novartis. https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019. Accessed February 28, 2019.
133. U.S. Food & Drug Administration, Office of the Commissioner. FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma: Yescarta is the second gene therapy product approved in the U.S. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm581216.htm. Updated March 21, 2018. Accessed March 22, 2019.
134. Novartis Pharma. Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma | Novartis. https://www.novartis.com/news/media-releases/kymriahr-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma. Accessed February 18, 2019.
135. European Medicines Agency. Yescarta: axicabtagene ciloleucel. https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta. Updated January 23, 2019. Accessed March 22, 2019.
136. Das RK, Vernau L, Grupp SA, Barrett DM. Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers. Cancer Discov. 2019. doi:10.1158/2159-8290.CD-18-1314.
137. Clague RB, Herold M, Bayer M, Tauchmannová H, Ferencik M, Killinger Z. Dictionary of Rheumatic Disease: Naive lymphocytes. 1. Aufl. s.l.: Springer Verlag Wien; 2009. http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=305925.
138. Frumento G, Zheng Y, Aubert G, et al. Cord blood T cells retain early differentiation phenotype suitable for immunotherapy after TCR gene transfer to confer EBV specificity. Am J Transplant. 2013;13(1):45-55. doi:10.1111/j.1600-6143.2012.04286.x.
